临床前期系统性硬化症的纵向全局转录组分析揭示与疾病进展相关的分子变化
对33例临床前期系统性硬化症(PreSSc)参与者和16名健康对照者采集基线和随访(平均4.2年)的外周血细胞进行RNA测序和模块分析,基线PreSSc与健康对照相比有2889个差异表达基因,干扰素信号是唯一激活的通路;随访时14例(42.4%)出现进展迹象,进展与基线临床特征或基线外周血细胞转录模块无关,稳定的PreSSc中下调的细胞毒性/NK细胞和蛋白质合成模块正常化,而进展的PreSSc则持续下调,外周血细胞中NK特征降低与系统性硬化症进展相关。
要点
- 临床前期系统性硬化症在转录组水平已存在分子差异,干扰素信号是唯一激活的通路。
- 随访平均4.2年,42.4%(14/33)的临床前期系统性硬化症参与者出现进展迹象。
- 外周血细胞中NK细胞特征降低与系统性硬化症进展相关。
核心结论
- 临床前期系统性硬化症参与者具有独特的基因表达谱,表明转录组水平的分子差异在临床前期阶段已经存在。
- 外周血细胞中降低的NK特征与系统性硬化症随时间进展相关。
研究设计与样本
- 研究纳入33例临床前期系统性硬化症参与者和16名健康对照者,在基线和随访(平均4.2年)时采集临床数据和外周血细胞。
- 通过RNA测序进行全局基因表达谱分析,并进行模块分析。
主要发现
- 基线临床前期系统性硬化症与健康对照比较,有2889个差异表达基因。
- 干扰素信号是前几位过度代表通路中唯一激活的通路。
- 与健康对照相比,临床前期系统性硬化症样本中有10个模块显著降低(与淋巴谱系、细胞毒性/NK细胞和红细胞生成相关)。
- 随访时14例(42.4%)参与者出现进展迹象(进展型临床前期系统性硬化症),19例保持稳定临床前期阶段(稳定型临床前期系统性硬化症)。
- 进展与基线临床特征或基线外周血细胞转录模块无关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate peripheral blood cell (PBCs) global gene expression profile of SSc at its preclinical stage (PreSSc) and to characterize the molecular changes associated with progression to a definite disease over time. MATERIAL AND METHODS: Clinical data and PBCs of 33 participants with PreSSc and 16 healthy controls (HCs) were collected at baseline and follow-up (mean 4.2 years). Global gene expression profiling was conducted by RNA sequencing and a modular analysis was performed. RESULTS: Comparison of baseline PreSSc to HCs revealed 2889 differentially expressed genes. Interferon signalling was the only activated pathway among top over-represented pathways. Moreover, 10 modules were significantly decreased in PreSSc samples (related to lymphoid lineage, cytotoxic/NK cell, and erythropoiesis) in comparison to HCs. At follow-up, 14 subjects (42.4%) presented signs of progression (evolving PreSSc) and 19 remained in stable preclinical stage (stable PreSSc). Progression was not associated with baseline clinical features or baseline PBC transcript modules. At follow-up stable PreSSc normalized their down-regulated cytotoxic/NK cell and protein synthesis modules while evolving PreSSc kept a down-regulation of cytotoxic/NK cell and protein synthesis modules. Transcript level changes of follow-up vs baseline in stable PreSSc vs evolving PreSSc showed 549 differentially expressed transcripts (336 up and 213 down) with upregulation of the EIF2 Signalling pathway. CONCLUSIONS: Participants with PreSSc had a distinct gene expression profile indicating that molecular differences at a transcriptomic level are already present in the preclinical stages of SSc. Furthermore, a reduced NK signature in PBCs was related to SSc progression over time.
引用
- Bellocchi C, Beretta L, Wang X, et al. Longitudinal global transcriptomic profiling of preclinical systemic sclerosis reveals molecular changes associated with disease progression. Rheumatology (Oxford). 2023. PMID: 36040182. doi:10.1093/rheumatology/keac492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。